Autoimmune tolerance eliminates relapses but fails to halt progression in a model of multiple sclerosis

J Neuroimmunol. 2005 Aug;165(1-2):41-52. doi: 10.1016/j.jneuroim.2005.04.009.

Abstract

To date there has been poor translation of immunotherapies from rodent models to treatment of progressive multiple sclerosis (MS). In the robust, relapsing Biozzi ABH mouse model of MS, using a combination of a transient deletion of T cells followed by intravenous (i.v.) myelin antigen administration, established relapsing disease in EAE can be effectively silenced. However, when treatment was initiated in late stage chronic-relapsing disease, despite inhibition of further relapses, mice demonstrated evidence of disease progression shown by a deterioration in mobility and development of spasticity and indicates that targeting relapsing, immunological components of MS alone is unlikely to be sufficient to control progression in the late stages of MS.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adoptive Transfer
  • Animals
  • Antibodies, Monoclonal / administration & dosage
  • CD4 Antigens / immunology
  • Chronic Disease
  • Disease Models, Animal
  • Disease Progression
  • Drug Therapy, Combination
  • Encephalomyelitis, Autoimmune, Experimental / immunology*
  • Encephalomyelitis, Autoimmune, Experimental / pathology
  • Encephalomyelitis, Autoimmune, Experimental / prevention & control
  • Immune Tolerance / immunology*
  • Injections, Intravenous
  • Lymphocyte Depletion
  • Mice
  • Mice, Biozzi
  • Mice, SCID
  • Multiple Sclerosis, Chronic Progressive / immunology
  • Multiple Sclerosis, Relapsing-Remitting / immunology*
  • Multiple Sclerosis, Relapsing-Remitting / prevention & control
  • Myelin Proteolipid Protein / administration & dosage
  • Myelin Proteolipid Protein / immunology
  • Secondary Prevention
  • Spinal Cord / cytology
  • Spinal Cord / immunology
  • Spinal Cord / transplantation
  • Spleen / cytology
  • Spleen / immunology
  • Spleen / transplantation

Substances

  • Antibodies, Monoclonal
  • CD4 Antigens
  • Myelin Proteolipid Protein